The disease-driven dysregulation of YAP/TAZ appears to be a critical element in the MASLD progression, contributing to hepatocyte dysfunction, inflammation, and fibrosis. This evidence concerns the gene YAP1 and metabolic dysfunction-associated steatotic liver disease.